• Lambda Protein Phosphatase (RNase-free): Precision Dephospho

  2026-06-09

  Discover how Lambda Protein Phosphatase (RNase-free) empowers advanced study of protein phosphorylation in circadian biology. This article dissects its unique mechanistic advantages and practical protocols, offering new perspectives for precision research.

• Baicalin Restores Adult Visual Cortex Plasticity in Amblyopi

  2026-06-08

  A recent study demonstrates that baicalin, a flavone glycoside from Scutellaria baicalensis, reactivates ocular dominance plasticity and restores vision in adult mice with amblyopia. These findings establish a mechanistic link between GABAergic inhibition reduction and renewed cortical flexibility, suggesting new pharmacological strategies for treating neurodevelopmental visual disorders.

• Z-LEHD-FMK: Advancing Caspase-9 Inhibition in Translational

  2026-06-08

  Explore the advanced role of Z-LEHD-FMK as an irreversible caspase-9 inhibitor in translational apoptosis research. This article uniquely bridges mechanistic insights with experimental design, highlighting new findings and optimizing assay strategies.

• Puromycin Aminonucleoside: Mechanisms, Models, and Protocols

  2026-06-07

  Puromycin aminonucleoside, the aminonucleoside moiety of puromycin, is widely used to induce podocyte injury and nephrotic syndrome in animal models. It enables reproducible glomerular lesion induction and proteinuria for studying focal segmental glomerulosclerosis (FSGS). This article clarifies its mechanisms, protocol benchmarks, and common research pitfalls.

• Rucaparib (AG-014699): Unveiling PARP1 Inhibition Beyond DNA

  2026-06-06

  Explore how Rucaparib (AG-014699) advances cancer biology research by modulating PARP1 and the DNA damage response. This article uniquely examines cell death mechanisms and transporter-mediated disposition, offering insights for sophisticated assay design.

• Deferasirox: Oral Iron Chelator for Advanced Cancer and Iron

  2026-06-05

  Deferasirox redefines experimental iron chelation by integrating robust workflow compatibility, selective iron targeting, and mechanistic depth, making it the oral iron chelator of choice for both metabolic and oncological research. Recent advances in nutrient sensing and ferritinophagy provide actionable insights for designing assays that interrogate iron metabolism and cell death pathways.

• Biotin-tyramide for Subcellular Proximity Labeling and RNA M

  2026-06-05

  Unlock the power of biotin-tyramide for spatially resolved proximity labeling and functional mapping of RNA-binding proteins. Discover how this advanced biotin phenol reagent enables precise, enzyme-mediated signal amplification beyond conventional IHC and ISH.

• Nutlin-3a: Redefining MDM2 Inhibition for Functional Cancer

  2026-06-04

  Explore how Nutlin-3a, a potent MDM2 inhibitor, enables precise manipulation of the p53 pathway for advanced cancer research. This article uniquely bridges molecular mechanism, protocol optimization, and translational relevance, offering actionable insights beyond current literature.

• Oxaliplatin in Cancer Research: Protocols, Synergies, and Tr

  2026-06-04

  Oxaliplatin, a platinum-based chemotherapeutic agent, excels in preclinical and translational cancer research through robust DNA adduct formation and apoptosis induction. This article provides actionable workflow enhancements, highlights novel synergy with PAK1 inhibition in colorectal cancer, and delivers advanced troubleshooting for reproducible, high-impact data.

• RIPA Lysis Buffer Strong: Advancing Translational Protein Sc

  2026-06-03

  This thought-leadership article bridges mechanistic insight and strategic guidance for translational researchers using RIPA Lysis Buffer (Strong, without inhibitors). It examines the buffer’s role in extracting high-integrity proteins from challenging samples, underlining its impact on workflows from basic discovery to translational research—particularly where biochemical fidelity, assay precision, and the flexibility to tailor inhibitor cocktails are paramount. By synthesizing evidence from mechanistic studies and leading-edge translational research, the article positions APExBIO’s solution as a pivotal tool for reliable protein analysis and discusses implications for next-generation therapeutic development.

• HOXC8 Suppresses Pyroptosis and Promotes NSCLC Growth via Ca

  2026-06-03

  The reference study uncovers a novel regulatory mechanism in non-small cell lung carcinoma (NSCLC), demonstrating that HOXC8 suppresses pyroptotic cell death by repressing caspase-1 transcription. This finding connects epigenetic control to tumor cell survival, with implications for understanding cell death pathways in cancer biology.

• Parathyroid hormone (1-34) (human): Atomic Mechanisms & Rese

  2026-06-02

  Parathyroid hormone (1-34) (human) is a potent PTH1R agonist essential for bone metabolism and advanced kidney research. This article delivers atomic, verifiable facts on its biological action, workflow integration, and assay parameters for high-fidelity disease modeling.

• Deferasirox: Oral Iron Chelator Empowering Experimental Onco

  2026-06-02

  Deferasirox, a clinically validated oral iron chelator, unlocks new dimensions for cancer research and iron overload modeling. Its unique mechanism—modulating iron metabolism and cell death pathways—positions it as an indispensable tool for dissecting ferroptosis, apoptosis, and metabolic adaptation in the laboratory.

• Pexmetinib (ARRY-614): Advanced Protocols for Cytokine Inhib

  2026-06-01

  Pexmetinib (ARRY-614) empowers researchers to dissect dual kinase signaling with precision, unlocking new levels of control in cytokine synthesis assays. This guide covers optimized workflows, troubleshooting, and the latest mechanistic insight for inflammation and myelodysplastic syndromes research.

• GSK3 Inhibition as a Host-Directed Strategy Against M. tuber

  2026-06-01

  A recent study demonstrates that inhibiting glycogen synthase kinase 3 (GSK3) impairs Mycobacterium tuberculosis (Mtb) growth within human macrophages, highlighting a host-directed therapeutic strategy. By integrating kinase inhibitor screening, CRISPR knockout, and phospho-proteomics, the research elucidates how targeting host signaling pathways can enhance innate antimicrobial responses and potentially reduce antibiotic resistance.

566 records 7/38 page Previous Next First page 上5页 678910 下5页 Last page